Latest news with #SupernusPharmaceuticals
Yahoo
28-05-2025
- Business
- Yahoo
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference
ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 2:00 p.m. ET in New York City. Investors interested in arranging a meeting with company management during the conference should contact the Jefferies conference coordinator. A live audio webcast of the presentation can be accessed here or by visiting Events & Presentations in the Investor Relations section on the Company's website at An archived replay of the webcast will be available for 60 days on the Company's website following the conference. About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for epilepsy, depression, and other CNS disorders. For more information, please visit Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company's ability to sustain and increase its profitability; the Company's ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company's corporate strategy; the Company's future financial performance and projected expenditures; the Company's ability to increase the number of prescriptions written for each of its products and the products of its subsidiaries; the Company's ability to increase its net revenue from its products and the products of its subsidiaries; the Company's ability to commercialize its products and the products of its subsidiaries; the Company's ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company's product research and development activities, including the timing and progress of the Company's clinical trials, and projected expenditures; the Company's ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company's product candidates; the Company's ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company's expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company's product candidates; the accuracy of the Company's estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company's ability to increase its manufacturing capabilities for its products and product candidates; the Company's projected markets and growth in markets; the Company's product formulations and patient needs and potential funding sources; the Company's staffing needs; changes to laws and regulations applicable to our industry, the impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs; and other risk factors set forth from time to time in the Company's filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events. CONTACTS: Jack A. Khattar, President and CEOTimothy C. Dec, Senior Vice President and CFOSupernus Pharmaceuticals, Inc.(301) 838-2591 or INVESTOR CONTACT:Peter VozzoICR Healthcare(443) in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-05-2025
- Business
- Yahoo
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock?
Investors in Supernus Pharmaceuticals, Inc. SUPN need to pay close attention to the stock based on moves in the options market lately. That is because the June 20, 2025 $30 Call had some of the highest implied volatility of all equity options today. Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy. Clearly, options traders are pricing in a big move for Supernus Pharmaceuticals shares, but what is the fundamental picture for the company? Currently, Supernus Pharmaceuticals is a Zacks Rank #3 (Hold) in the Medical - Generic Drugs industry that ranks in the Bottom 16% of our Zacks Industry Rank. Over the last 60 days, one analyst has increased the earnings estimates for the current quarter, while none dropped the estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from 46 cents per share to 48 cents in that period. Given the way analysts feel about Supernus Pharmaceuticals right now, this huge implied volatility could mean there's a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected. Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. In addition to impressive profit potential, these trades can actually reduce your risk. Click to see the trades now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Supernus Pharmaceuticals, Inc. (SUPN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
08-05-2025
- Business
- Yahoo
Collegium Pharmaceutical (COLL) Q1 Earnings: What To Expect
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting earnings tomorrow after market close. Here's what to look for. Collegium Pharmaceutical beat analysts' revenue expectations by 1% last quarter, reporting revenues of $181.9 million, up 21.5% year on year. It was a strong quarter for the company, with a solid beat of analysts' EPS estimates and full-year revenue guidance meeting analysts' expectations. Is Collegium Pharmaceutical a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Collegium Pharmaceutical's revenue to grow 19.2% year on year to $172.8 million, improving from its flat revenue in the same quarter last year. Adjusted earnings are expected to come in at $1.45 per share. Collegium Pharmaceutical Total Revenue Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Collegium Pharmaceutical has missed Wall Street's revenue estimates four times over the last two years. Looking at Collegium Pharmaceutical's peers in the branded pharmaceuticals segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Bristol-Myers Squibb's revenues decreased 5.6% year on year, beating analysts' expectations by 3.9%, and Supernus Pharmaceuticals reported revenues up 4.3%, topping estimates by 1.3%. Bristol-Myers Squibb traded down 1.3% following the results. Read our full analysis of Bristol-Myers Squibb's results here and Supernus Pharmaceuticals's results here. There has been positive sentiment among investors in the branded pharmaceuticals segment, with share prices up 5.9% on average over the last month. Collegium Pharmaceutical is up 10% during the same time and is heading into earnings with an average analyst price target of $42.80 (compared to the current share price of $27.95). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
Yahoo
07-05-2025
- Business
- Yahoo
Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting results tomorrow before the bell. Here's what you need to know. Royalty Pharma missed analysts' revenue expectations by 1.9% last quarter, reporting revenues of $594 million, flat year on year. It was a slower quarter for the company, with a decent beat of analysts' EPS estimates. Is Royalty Pharma a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Royalty Pharma's revenue to be flat year on year at $570 million, improving from the 17% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.95 per share. Royalty Pharma Total Revenue Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Royalty Pharma has missed Wall Street's revenue estimates five times over the last two years. Looking at Royalty Pharma's peers in the branded pharmaceuticals segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Bristol-Myers Squibb's revenues decreased 5.6% year on year, beating analysts' expectations by 3.9%, and Supernus Pharmaceuticals reported revenues up 4.3%, topping estimates by 1.3%. Bristol-Myers Squibb traded down 1.3% following the results. Read our full analysis of Bristol-Myers Squibb's results here and Supernus Pharmaceuticals's results here. There has been positive sentiment among investors in the branded pharmaceuticals segment, with share prices up 5.9% on average over the last month. Royalty Pharma is up 3.8% during the same time and is heading into earnings with an average analyst price target of $39.74 (compared to the current share price of $32.02). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
Yahoo
07-05-2025
- Business
- Yahoo
Supernus Pharmaceuticals's (NASDAQ:SUPN) Q1 Sales Beat Estimates But Full-Year Sales Guidance Misses Expectations
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported revenue ahead of Wall Street's expectations in Q1 CY2025, with sales up 4.3% year on year to $149.8 million. On the other hand, the company's full-year revenue guidance of $615 million at the midpoint came in 1.6% below analysts' estimates. Its GAAP loss of $0.21 per share was significantly below analysts' consensus estimates. Is now the time to buy Supernus Pharmaceuticals? Find out in our full research report. Supernus Pharmaceuticals (SUPN) Q1 CY2025 Highlights: Revenue: $149.8 million vs analyst estimates of $147.9 million (4.3% year-on-year growth, 1.3% beat) EPS (GAAP): -$0.21 vs analyst estimates of -$0.01 (significant miss) Adjusted EBITDA: -$10.23 million vs analyst estimates of $49.3 million (-6.8% margin, significant miss) The company reconfirmed its revenue guidance for the full year of $615 million at the midpoint Operating Margin: -6.8%, down from -2.2% in the same quarter last year Market Capitalization: $1.81 billion 'Our first quarter results reflect, once again, double-digit revenue growth from our core products, as well as strong growth in adjusted operating earnings,' said Jack Khattar, President and CEO of Supernus. Company Overview With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals (NASDAQ:SUPN) develops and markets treatments for central nervous system disorders including epilepsy, ADHD, Parkinson's disease, and migraine. Sales Growth Examining a company's long-term performance can provide clues about its quality. Any business can have short-term success, but a top-tier one grows for years. Luckily, Supernus Pharmaceuticals's sales grew at a decent 10.7% compounded annual growth rate over the last five years. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers. Supernus Pharmaceuticals Quarterly Revenue Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Supernus Pharmaceuticals's recent performance shows its demand has slowed as its revenue was flat over the last two years. Supernus Pharmaceuticals Year-On-Year Revenue Growth Supernus Pharmaceuticals also breaks out the revenue for its most important segment, . Over the last two years, Supernus Pharmaceuticals's revenue was flat. This segment has outperformed its total sales during the same period, lifting the company's performance. This quarter, Supernus Pharmaceuticals reported modest year-on-year revenue growth of 4.3% but beat Wall Street's estimates by 1.3%.
